骨关节炎的单克隆抗体治疗

背景:在骨关节炎的发病过程中有大量炎症因子产生,针对炎症因子的抗体最近成为了研究热点。目的:概述治疗骨关节炎单克隆抗体的最新研究进展,为临床治疗骨关节炎提供参考。方法:利用计算机检索CNKI、万方、PubMed及Web of Science数据库2006年1月至2020年5月的相关文章,检索词为“骨关节炎,单克隆抗体,炎症因子,osteoarthritis,monoclonal antibodies,inflammatory factors”。查阅相关文章,最终共纳入69篇文献进行结果分析。结果与结论:①骨关节炎是一种炎症性、退行性疾病,与传统非类固醇类抗炎药相比,单克隆抗体因其靶向性好、不良反应小的特点,在治疗骨关节炎疼痛方面已显示出良好效果;②部分单克隆抗体会加大患者关节置换的风险,因此药物选择应当因人而异;③随着研究的不断深入,会有更多针对不同靶点的单克隆抗体产生,为临床治疗骨关节炎提供更多选择。

Monoclonal antibody therapy for osteoarthritis

BACKGROUND: Studies have shown that a large amount of inflammatory factors produce in the occurrence of osteoarthritis, and antibodies againstinflammatory factors have recently become a research hotspot.OBJECTIVE: To summarize the latest research progress of monoclonal antibodies for the treatment of osteoarthritis, and to provide references for the clinicaltreatment of osteoarthritis.METHODS: A computer search of CNKI, WanFang, PubMed and Web of Science databases was conducted for relevant articles published from January 2006 toMay 2020. The key words were “osteoarthritis;monoclonal antibody;inflammatory factors.” After consulting related articles, a total of 69 articles were finallyincluded for result analysis.RESULTS AND CONCLUSION: Osteoarthritis is an inflammatory and degenerative disease. Compared with traditional non-steroidal anti-inflammatory drugs,monoclonal antibodies have shown good effects in the treatment of osteoarthritis pain due to their good targeting and low side effects. Some monoclonalantibodies will increase the risk of joint replacement in patients, so the choice of drugs should vary from person to person. As research continues to deepen,more monoclonal antibodies against different targets will be produced, providing more options for clinical treatment of osteoarthritis.